Improved survival for women with stage i breast cancer in south-east Sweden: A comparison between two time periods before and after increased use of adjuvant systemic therapy

Acta Oncologica

Volumn 48, Issue 4, 2009, Pages 504-513

  Johansson, Patrik ^a   Fohlin, Helena ^b   Arnesson, Lars Gunnar ^b   Dufmats, Monika ^a   Nordenskjöld, Kerstin ^a   Nordenskjöld, Bo ^a   Stål, Olle ^a   Agrup, Mns ^b   Asking, Bengt ^c   Blomkvist, Tord ^d   Bång, Harald ^e   Dabrosin, Charlotta ^a   Einarsson, Eibert ^f   Gustavsson, Rune ^c   Klintenberg, Claes ^b   Linderholm, Barbro ^b   Malmstrm, Annika ^b   Malterling, Rebecka ^c   Sundquist, Marie ^g   Norberg, Bengt ^h   Rundcrantz, Ann ^e   Skoog, Peter ⁱ   Starkhammar, Hans ^b   Askmalm, Marie Stenmark ^b   Tejler, Gran ^j   Thorstenson, Sten ^g   Vahlin, Susanne ^b   Vitak, Bedrich ^b   more..

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c Ryhov County Hospital   (Sweden)

^d VRINNEVI HOSPITAL   (Sweden)

^e Motala General Hospital   (Sweden)

^f Eksj Hospital   (Sweden)

^g KALMAR COUNTY HOSPITAL   (Sweden)

^h Ryhov County Hospital   (Sweden)

ⁱ Vrnamo Hospital   (Sweden)

^j Vstervik Hospital   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYTOTOXIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; SWEDEN; TREATMENT DURATION; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CHEMISTRY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK; RISK ASSESSMENT; RISK FACTOR; SEGMENTAL MASTECTOMY; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYTOTOXINS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TREATMENT OUTCOME;

EID: 65549097314     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860902718754     Document Type: Article

References (35)

1. Levi F, Lucchini F, Negri E, La Vecchia C. The decline in cancer mortality in the European Union, 1988-1996. Eur J Cancer 2000;/36:/1965-8. (Pubitemid 30734704)
2. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000;/335:/1822.
3. Mouridsen HT, Bjerre KD, Christiansen P, Jensen M-B, Møller S. Improvement of prognosis in breast cancer in Denmark 1977-2006, based on the nationwide reporting to the DBCG Registry. Acta Oncol 2008;/47:/525-36.
4. Felay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;/18:/581-92. (Pubitemid 46359643)
5. Tejler G, Norberg B, Nordenskjöld B on behalf of the South East Sweden Breast Cancer Group. Survival after treatment for breast cancer in a geographically defined population. Br J Surg 2004;91:1307-12.
6. Svenska bröstcancergruppen. Nationella riktlinjer fö r behandling av bröstcancer. http://www.swebcg.roc.se/natrik tlinjbrca2007.htm
7. Staol O, Hatschek T, Carstensen J, Nordenskjö ld B. DNA analysis in the management of breast cancer. Diagn Oncol 1991;/1:/140-54.
8. Staol O, Dufmats M, Hatschek T, Carstensen J, Klintenberg C, Rutqvist LE, et al. S-phase fraction is a prognostic factor in stage I breast carcinoma. J Clin Oncol 1993;/9:/1717-22.
9. Remvikos Y, Mosseri V, Asselain B, Fourquet A, Durand JC, Pouillart P, et al. S-phase fractions of breast cancer predict overall and post-relapse survival. Eur J Cancer 1997;/4:/ 581-6.
10. Daidone MG, Silvestrini R. Progostic and predictive value of proliferation indices in adjuvant therapy of breast cancer. J Natl Cancer Inst 2001;/30:/27-35.
11. Latinovic L, Heinze G, Birner P, Samonigg H, Hausmaninger H, Kubista E, et al. Prognostic relevance of three histological grading methods in breast cancer. Int J Oncol 2001;/6:/1271-7.
12. Rosen PP, Groschen S, Saigo PE, Kinne DW, Hellman S. A long term, follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989;/7:/355-66.
13. Sydöstra bröstcancergruppen. Va°rdprogram för bröstcancer stadium I. Onkologiskt Centrum för Sydöstra Sjukva°rdsregionen, Regionsjukhuseti Linköping, 1983.
14. Sydöstsvenska bröstcancergruppen. Va°rdprogram för brö stcancer. Sydö stsvenska Bröstcancergruppen och Onkologiskt Centrum för Sydöstra Sjukva°rdsregionen, Universitetssjukhuset i Linköping, 1992.
15. Early Breast Cancer Trialist's Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-717.
16. Swedish Breast Cancer Cooperative Group (SBCCG). Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996;88:1543-9.
17. Ejlertsen B, Mouridsen HT, Jensen M, Andersen J, Cold S, Edlund P, et al. Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer 2007;43:877-84.
18. Fernö M, Sta°l O, Baldetorp B, Hatschek T, Källström A-C, Malmström P, et al. South Sweden Breast Cancer Group and South-East Sweden Breast Cancer Group. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. Breast Cancer Res Treat 2000;/ 59:/69-76.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958;/53:/457-81.
20. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley; 1980.
21. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;/34:/187-220.
22. Hammar M, Brynhildsen J, Dabrosin L, Frisk J, Lindgren R, Nedstrand E, et al. Hormonal replacement therapy and previous use of oral contraceptives among Swedish women. Maturitas 1996;/25:/193-9.
23. Brynhildsen J, Bjö rs E, Skarsga°rd C, Hammar M. Is hormone replacement therapy a risk factor for low back pain among postmenopausal women? SPINE 1998;/7:/ 809-13.
24. Ekblad S, Bergendahl A, Enler P, Ledin T, Mö llen C, Hammar M. Disturbances in postural balance are common in postmenopausal women with vasomotor symptoms. Climacteric 2000;/3:/192-8.
25. Olsson HL, Ingvar C, Bladström A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003;/6:/ 1387-92. (Pubitemid 36297767)
26. Fernö M, Baldetorp B, Bendahl PO, Borg A, Ewers SB, Olsson H, et al. Recurrence-free survival in breast cancer improved by adjuvant tamoxifen especially for progesterone receptor positive tumours with a high proliferation. Breast Cancer Res Treat 1995;/36:/23-34.
27. Goldhirsch A, Colleoni M, Domenighetti G, Gelber RD. Systemic treatments for women with breast cancer: Outcome with relation to screening for the disease. Ann Oncol 2003;/14:/1212-4.
28. Jatoi I, Miller AB. Why is breast-cancer mortality declining? Lancet Oncol 2003;/4:/251-4.
29. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant adjuvant chemotherapy. NEJM 1997;/337:/949-55.
30. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen. Lancet 1999;/353:/1641-8.
31. Schuetz F, Diel IJ, Pueschel M, von Holst T, Solomayer EF, Lange S, et al. Reduced incidence of distant metastastis and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol 2007;/196:/342e1-9.
32. Desmedt C, Sotiriou C. Proliferation: The most prominent predictor of clinical outcome in breast cancer. Cell Cycle 2006;/5:/2198-202.
33. Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005;/65:/4059-66.
34. Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006;/8:/R25.
35. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;/98:/262-72.